WO2001081339A1 - Composes pour le traitement ou la prevention du paludisme et procedes pour le traitement du paludisme - Google Patents
Composes pour le traitement ou la prevention du paludisme et procedes pour le traitement du paludisme Download PDFInfo
- Publication number
- WO2001081339A1 WO2001081339A1 PCT/JP2001/003619 JP0103619W WO0181339A1 WO 2001081339 A1 WO2001081339 A1 WO 2001081339A1 JP 0103619 W JP0103619 W JP 0103619W WO 0181339 A1 WO0181339 A1 WO 0181339A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- malaria
- antibiotic
- substance
- salt
- malaria parasite
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Malarial parasites that infect humans include Pl smodium fal ciparum, belonging to the spore family, Plasmodium vivax, Plasmodium vivax, Plasmodium malailae., And oval malaria parasites. Plasmodium ovale is n addition, there are a malaria parasite that infects monkeys, malaria parasites to infection in mice.
- the antibiotic SF2487 substance has a tetronic acid moiety as an acidic group in its structure.
- the chemical structure is different from that of monensin, digericin and salinomycin, which have a carboxylic acid as an acidic group.
- the present inventors speculated that the antibiotic SF2487 having antiviral activity and antibacterial activity has a different pharmacological mechanism from conventionally known anti-malarial drugs of the type of polyether antibiotics. Accordingly, the present inventors conducted a test in which sodium bovine SF 2487 substance sodium salt was allowed to act on Eksmodil falciparum cultured in a test tube and infected with human erythrocytes.
- composition for treating or preventing a malaria disease.
- a human host infected with malaria parasite but not yet showing the disease symptoms of malaria has the following formula (I): Administer orally or parenterally the SF 2 487 substance or its pharmaceutically acceptable salt in an amount sufficient to prevent the growth of the malaria parasite in the host A method for preventing malaria disease is provided.
- the following raw material components were mixed at an appropriate ratio, and the mixture was formed by a tableting method. Tablets weighing 300 mg per tablet were obtained.
- the composition per tablet was as follows.
- Plasmodium falciparum Plasmodium falciparum FCR-3 strain (ATCC 30932) and Honduras-1 strain (ATCC 30950) were cultured as malaria parasites.
- the culture medium for malaria parasite culture was prepared by filtering and sterilizing PRMI 1640 medium, adjusting the pH to 7.4, and adding human serum containing red blood cells to a concentration of 10% (by weight). is there. After adjusting the hematocrit value of the medium (the proportion of red blood cells in the red blood cell suspension) to 5%, the medium was added to each well of a 24-well culture plate. The medium in each well was inoculated with P. falciparum.
- Erythrocyte infection rate (%)-Total erythrocyte count 100 From the malaria parasite culture prepared above, the malaria parasite-infected erythrocytes are collected by centrifugation, and the collected erythrocytes are washed with a serum-containing PRMI 1640 medium, and then the malaria parasite is recovered. Uninfected red blood cells were added. In this way, a malaria parasite culture solution containing erythrocytes, the initial infection rate of which was adjusted to 0.3%, was prepared. The hematocrit value of the culture at this time is 3%.
- test compound used in the experiment was prepared in advance as a solution dissolved in sterilized water, dimethylformamide (DMF), or dimethylsulfoxide (DMS0). 2. Measurement test of the activity of the test compound that inhibits the growth of the malaria parasite
- the aforementioned P. falciparum malaria parasite culture solution (having an initial erythrocyte infection rate of 0.3%), which had been prepared in advance as described above, was added to each well by pipetting 990 to 9951. By gentle pipetting, the malaria parasite-infected and uninfected erythrocytes were uniformly suspended in the medium in each well.
- a is the value at the start of the malaria parasite culture test, that is, when the malaria parasite culture solution is added to the medium in each well.
- the erythrocyte infection rate (%) by the malaria parasite in the medium that is, the same as the initial infection rate of 0.3% of the inoculated malaria parasite culture solution
- b is the treatment with the medium containing the added test compound.
- the value of (ca) indicates the degree of growth of malaria parasites cultured in the absence of the test compound
- the value of (ba) indicates the growth of malaria parasites cultured in the presence of the test compound.
- F28-7 strain a wild strain of mouse breast cancer-derived FM3A cells
- the culture medium for culturing the F28-7 cell line was prepared by adding fetal calf serum inactivated to ES medium to a concentration of 2%. They were cultured F28-7 strain cells of test in this medium C0 2 5% Under including air 37 ° C. Under these conditions, the doubling time of the F28-7 cell line derived from mouse breast cancer was about 12 hours.
- the above-described medium for culturing the F28-7 strain cell was placed in each well of a 24-well culture plate.
- the test compound solution was added to the medium in each well of the 24-well culture plate in an amount of 5 to 10 1 each, and the final concentration of the test compound added to the medium in each well was 1 ⁇ . 10 was adjusted to one 4 ⁇ 1 X 10_ 6 M.
- the test was performed in duplicate or triplicate.
- 10 1 of sterilized water, DMF, or DMS0 was added, but no test compound was added.
- the F28-7 cell line was cultured under the above culture conditions for 48 hours. Thereafter, the number of cells of the F28-7 cell line was counted using a cell counter (CC-108, Toa Medical Electronics) for each well in the treated section and the control section (untreated).
- the inhibitory activity of the test compound on the growth of the F28-7 cell line was determined by the number of F28-7 cell lines in the cell culture in the wells cultured in the presence of the added test compound, and the number of the test compound. Judgment was made from the growth rate (%) of the F28-7 cell line defined by the following formula based on the number of the F28-7 cell lines in the control group cultured in the absence of the cell. The cytotoxicity of the test compound is evaluated from the cell proliferation rate (%) determined in this way.
- F28-7 cell growth rate (%) ( ⁇ d X 100
- A represents the number of strain F28-7 cells in each well in the treated and control sections at the start of culture.
- B indicates the number of cells of the F28-7 cell line after culturing for 48 hours in the wells of the control (untreated) in which the test compound was not added. Shows the number of F28-7 strain cells after 48 hours of culture in the wells of the treatments cultured in the presence of the test compound.
- the value of (B-A) indicates that the cells were cultured in the absence of the test compound.
- the value of (CA) indicates the degree of proliferation of the F28-7 cell line cultured in the presence of the test compound, and indicates the degree of proliferation of the F28-7 cell line. (%) Is shown in Table 2 below for the sample SF 2487 substance and black quinine (comparison).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001578429A JP4806510B2 (ja) | 2000-04-26 | 2001-04-26 | マラリア病の治療または予防用組成物、およびマラリア病の治療方法 |
AU52598/01A AU5259801A (en) | 2000-04-26 | 2001-04-26 | Compositions for treating or preventing malaria and method of treating malaria |
DE60136067T DE60136067D1 (de) | 2000-04-26 | 2001-04-26 | Gemische zur behandlung oder prävention von malaria und verfahren zur behandlung von malaria |
EP01925951A EP1295881B1 (en) | 2000-04-26 | 2001-04-26 | Compositions for treating or preventing malaria and method of treating malaria |
US10/258,435 US6939892B2 (en) | 2000-04-26 | 2001-04-26 | Compositions for treating or preventing malaria and method of treating malaria |
CA002411966A CA2411966C (en) | 2000-04-26 | 2001-04-26 | Compositions for treating or preventing malaria and method of treating malaria |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-126369 | 2000-04-26 | ||
JP2000126369 | 2000-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001081339A1 true WO2001081339A1 (fr) | 2001-11-01 |
Family
ID=18636160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/003619 WO2001081339A1 (fr) | 2000-04-26 | 2001-04-26 | Composes pour le traitement ou la prevention du paludisme et procedes pour le traitement du paludisme |
Country Status (8)
Country | Link |
---|---|
US (1) | US6939892B2 (ja) |
EP (1) | EP1295881B1 (ja) |
JP (1) | JP4806510B2 (ja) |
AT (1) | ATE410423T1 (ja) |
AU (1) | AU5259801A (ja) |
CA (1) | CA2411966C (ja) |
DE (1) | DE60136067D1 (ja) |
WO (1) | WO2001081339A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6547139B1 (en) | 1998-07-10 | 2003-04-15 | Welch Allyn Data Collection, Inc. | Method and apparatus for extending operating range of bar code scanner |
WO2009039475A1 (en) * | 2007-09-21 | 2009-03-26 | Omnicare Inc. | Automated label verify systems and methods for dispensing pharmaceuticals |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0305086A2 (en) * | 1987-08-13 | 1989-03-01 | Eli Lilly And Company | Antibiotic A80577 and process for its production |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4283493A (en) * | 1978-09-22 | 1981-08-11 | Hoffmann-La Roche Inc. | Process of producing antibiotic X-14766A by a streptomyces |
US4221724A (en) * | 1978-09-22 | 1980-09-09 | Hoffmann-La Roche Inc. | Antibiotic X-14766A |
AU531276B2 (en) * | 1978-11-29 | 1983-08-18 | F. Hoffmann-La Roche & Co. | Antibacterial urethane derivatives |
JPS5592387A (en) * | 1978-12-29 | 1980-07-12 | Taisho Pharmaceut Co Ltd | Antibiotic substance tm-531 |
US4375542A (en) * | 1980-01-17 | 1983-03-01 | Schering Corporation | Kijanimicin antibiotics and derivatives thereof |
JPS5978120A (ja) * | 1982-10-28 | 1984-05-04 | Meiji Seika Kaisha Ltd | 抗ウイルス剤 |
US4496549A (en) * | 1983-01-17 | 1985-01-29 | American Cyanamid Company | Treatment of malaria with antibiotics |
US4578468A (en) * | 1984-03-26 | 1986-03-25 | American Cyanamid Company | Antibiotic LL-D42067β |
US4774184A (en) * | 1984-03-26 | 1988-09-27 | American Cyanamid Company | Culture and process for producing antibiotic LL-D42067alpha |
US4551533A (en) * | 1984-03-26 | 1985-11-05 | American Cyanamid Company | Antibiotic LL-D42067α |
US4650802A (en) * | 1984-03-26 | 1987-03-17 | American Cyanamid Company | Methods and compositions for treating protozoal infections with a novel antibiotic |
US4859598A (en) * | 1984-03-26 | 1989-08-22 | American Cyanamid Company | Antibiotic LL-D42067β |
JPS63192792A (ja) * | 1987-02-06 | 1988-08-10 | Meiji Seika Kaisha Ltd | 新規抗生物質sf2487物質及びその製造法 |
US4876273A (en) * | 1987-08-13 | 1989-10-24 | Eli Lilly And Company | Antibotic A80577 and process for its production |
US5098834A (en) * | 1988-05-02 | 1992-03-24 | Eli Lilly And Company | Process for producing antibiotic A8210 which comprises cultivating Actinomadura Fibrosa sp nov. NRRL 18348, or an A82810-producing mutant thereof |
-
2001
- 2001-04-26 WO PCT/JP2001/003619 patent/WO2001081339A1/ja active Application Filing
- 2001-04-26 US US10/258,435 patent/US6939892B2/en not_active Expired - Fee Related
- 2001-04-26 EP EP01925951A patent/EP1295881B1/en not_active Expired - Lifetime
- 2001-04-26 CA CA002411966A patent/CA2411966C/en not_active Expired - Fee Related
- 2001-04-26 DE DE60136067T patent/DE60136067D1/de not_active Expired - Lifetime
- 2001-04-26 JP JP2001578429A patent/JP4806510B2/ja not_active Expired - Fee Related
- 2001-04-26 AT AT01925951T patent/ATE410423T1/de not_active IP Right Cessation
- 2001-04-26 AU AU52598/01A patent/AU5259801A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0305086A2 (en) * | 1987-08-13 | 1989-03-01 | Eli Lilly And Company | Antibiotic A80577 and process for its production |
Also Published As
Publication number | Publication date |
---|---|
EP1295881A1 (en) | 2003-03-26 |
JP4806510B2 (ja) | 2011-11-02 |
US6939892B2 (en) | 2005-09-06 |
DE60136067D1 (de) | 2008-11-20 |
EP1295881A4 (en) | 2006-10-18 |
EP1295881B1 (en) | 2008-10-08 |
AU5259801A (en) | 2001-11-07 |
US20030176492A1 (en) | 2003-09-18 |
ATE410423T1 (de) | 2008-10-15 |
CA2411966C (en) | 2008-11-18 |
CA2411966A1 (en) | 2002-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Warrell et al. | Treatment and prevention of malaria | |
TWI387456B (zh) | 用於治療瘧疾之二茂鐵氯奎(ferroquine)及黃花蒿素(artemisinin)衍生物之組合 | |
CN111265527B (zh) | 萘酚喹及其药学上可接受的盐在制备抗冠状病毒药物中的用途 | |
Kremsner | Clindamycin in malaria treatment | |
CN1833644B (zh) | 青蒿素及其衍生物二氢青蒿素、蒿甲醚、蒿乙醚、青蒿琥酯在制药中的应用 | |
CN101805285B (zh) | 含烟酸姜黄素酯衍生物及其制造方法和用途 | |
WO2006104292A1 (en) | Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts | |
Farthing et al. | Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS | |
WO2001081339A1 (fr) | Composes pour le traitement ou la prevention du paludisme et procedes pour le traitement du paludisme | |
WO2021060933A1 (ko) | Mmagnu2 화합물을 유효성분으로 함유하는 결핵균, 비결핵 항산균 또는 그람 양성균 감염 질환 예방 또는 치료용 조성물 | |
US4892876A (en) | Method for inhibiting HIV and an pharmaceutical composition therefor | |
CN111803484B (zh) | 奥替溴铵在制备抗肿瘤药物中的应用 | |
JP4382898B2 (ja) | 抗マラリア活性を有するペルオキシド誘導体 | |
JP4460709B2 (ja) | 新規マラリア予防・治療薬 | |
CN111317733B (zh) | 利福霉素类抗生素在制备抗黄热病毒感染药物中的应用 | |
JPH11228422A (ja) | 抗マラリア剤 | |
CN114159474B (zh) | 六神丸在制备治疗真菌性肺炎的药物中的应用 | |
WO2009072779A1 (en) | Composition comprising sodium meta-arsenite for treatment of hepatitis c | |
CN113318107B (zh) | 一种含氮化合物在制备抗真菌药物中的应用 | |
JP2643340B2 (ja) | ヒト後天性免疫不全症候群ウイルス感染阻害剤 | |
JPH0859471A (ja) | 抗マラリア剤 | |
CN110698457A (zh) | 一种抗金黄色葡萄球菌毒力和生物被膜形成的抑制剂Lo-叔丁酯及其用途 | |
JP2799368B2 (ja) | 抗原虫剤 | |
CN110818684A (zh) | 一种抗金黄色葡萄球菌毒力和生物被膜形成的抑制剂Lo-SH及其用途 | |
JPH0597665A (ja) | 抗マラリア剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO RU SG SI SK TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 578429 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001925951 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2411966 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10258435 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001925951 Country of ref document: EP |